BioCentury
ARTICLE | Top Story

Audentes inches up after pricing $75M IPO

July 20, 2016 7:00 AM UTC

Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) added $0.13 to $15.13 on its first day of trading Wednesday after raising $75 million through the sale of 5 million shares at $15 in an IPO. The IPO price valued the company at $315.3 million.

The company was aiming to sell 5 million shares at $14-$16. It filed in January to raise up to $86.3 million. BofA Merrill Lynch, Cowen, Piper Jaffray and Wedbush PacGrow are underwriters. ...